PNV - Banter and General Comments, page-6162

Great post.

There's a lot more to it than the company not meeting it's pre pandemic sales goals.

If that was the case, how do these posters explain our rise to $4?

I'm not saying the share price deserved to get to that level. What I'm saying is if the price boils down to those pre-pandemic predictions, what gives?

It's likely much more complex, and involves shorts, hype, traders, and mixed expectations on either side, as well as internal politics, leadership changes, new waves, etc.

The question should be, at the end of the day, how does this new product stack up to the existing standard of care? Will this change management of patients? Will surgeons want to use this product?

Those are much more simple questions, if you know the industry.